/
KPRX
$2.59-$0.05 (-1.89%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$11.7M
4M shares
52-week range
$1.76 – $3.01
66% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change$-652.61
Kiora Pharmaceuticals, Inc. Common Stock
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
www.kiorapharma.com- Employees
- 13
- IPO / List date
- Feb 13, 2015
- HQ
- ENCINITAS, CA
Held by traders on TradeandTell
No one on the platform currently holds KPRX.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-12-31 | 21,200 | $41.8K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2024-06-11 | 1-for-9reverse |
| 2022-09-27 | 1-for-40reverse |
| 2019-08-30 | 1-for-15reverse |
Recent trades on TradeandTell
No one on the platform has traded KPRX yet.
